Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa

NCT07783542 is registered in ClinicalTrials.gov with Oruka Therapeutics, Inc. as lead sponsor.

NCT NCT07783542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07783542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa
Lead sponsor
Oruka Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 21, 2026
Completion date
September 30, 2029
Enrollment
200 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa (hs)